Theralase Technologies Inc.

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

Theralase(R) Closes $CAN 2.66 Million Financing

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer